Clinical trials: Cardiac Insufficiency
Advanced Heart Failure
Hong Kong and Taiwan HM3 PMS
Hong Kong and Taiwan HM3 PMS is a prospective, single arm, post market surveillance is designed to evaluate clinical and functional outcomes with the HM3 LVAS as a treatment for advanced heart failure.
- Trial name
- NCT04703855
- Testing
- HeartMate 3™ left ventricular assist system (HM3 LVAS)
- Where
- 3 sites in Hong Kong, Taiwan
- Volunteers
- 3 people
- Sponsor
- Abbott Medical Devices
Heart Failure
Patient-Reported Outcome Measurement in Heart Failure Clinic
This is a randomized study evaluating the effect of routinely collecting a standardized questionnaire of heart failure health status during heart failure clinic visits.
- Trial name
- PRO-HF (NCT04164004)
- Testing
- Kansas City Cardiomyopathy Questionnaire-12
- Where
- United States
- Volunteers
- 1,249 people
- Sponsor
- Stanford University
Acute Pulmonary Edema
MIdazolam Versus MOrphine in Acute Pulmonary Edema (MIMO Trial)
Acute pulmonary edema (APE) is a common condition in the emergency room, associated with considerable mortality. The use of intravenous morphine in the treatment of APE remains controversial and Benzodiazepines have been…
- Trial name
- MIMO (NCT02856698)
- Testing
- Midazolam, Morphine
- Where
- 8 sites in Spain
- Volunteers
- 111 people
- Sponsor
- Alberto Dominguez-Rodriguez
Heart Failure
PEGASUS CRT Study: Atrial Support Study in Cardiac Resynchronization Therapy
This study will look at different pacing modes (how a device is programmed to pace one's heart), and how these modes may assist in one's daily activities and how one is feeling.
- Trial name
- PEGASUS CRT (NCT00146848)
- Testing
- Atrial support pacing through cardiac resynchronization therapy. Device: RENEWAL family of CRT-D devices
- Where
- United States
- Volunteers
- 1,742 people
- Sponsor
- Boston Scientific Corporation
Congestive Heart Failure, Emotions
Researching Emotions And Cardiac Health (REACH): Phase II
The focus of this study is to examine the feasibility, acceptability, and preliminary impact of our customized positive psychology (PP)-based health behavior intervention in a group of patients with mild to moderate heart failure…
- Conditions
- Congestive Heart Failure, Emotions, Patient Compliance
- Trial name
- REACH II (NCT02938052)
- Testing
- PP-based health behavior intervention
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Congenital Heart Disease With Fontan Circulation
An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.
The aim of this open-label (OL) trial is to study the long-term use of macitentan for up to 2 years in Fontan-palliated adult and adolescent patients beyond the 52 weeks of treatment in the parent RUBATO double-blind (DB) study…
- Trial name
- RUBATO OL (NCT03775421)
- Testing
- macitentan 10 mg
- Where
- 19 sites in United States, Australia and 9 more
- Volunteers
- 112 people
- Sponsor
- Actelion
Congestive Heart Failure, Left Bundle Branch Block
MIRACLE EF Clinical Study
This study is looking at whether the electrical treatment provided by a special type of pacemaker called a Cardiac Resynchronization Therapy (CRT) pacemaker may keep a patient's heart failure from getting worse.
- Conditions
- Congestive Heart Failure, Left Bundle Branch Block, Systolic Heart Failure
- Trial name
- MIRACLE EF (NCT01735916)
- Testing
- CRT-P Implant, CRT-P OFF
- Where
- 73 sites in United States, India and 3 more
- Volunteers
- 44 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure
Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF
This study will be a sequential multiple-dose escalation study that will enroll (randomize and dose) approximately 28 subjects in four cohorts consisting of 3 active and 1 placebo in Cohort 1 and 6 active and 2 placebo in…
- Trial name
- NCT02808585
- Testing
- PB1046 Injection
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Mitral Valve Insufficiency, Heart Failure
Effectiveness of Surgical Mitral Valve Repair Versus Medical Treatment for People With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure
Mitral regurgitation (MR), also known as mitral insufficiency, is a condition in which the heart's mitral valve, located between two of the heart's main chambers, does not firmly shut, allowing blood to leak backwards within the…
- Trial name
- SMMART-HF (NCT00608140)
- Testing
- Surgical mitral valvuloplasty with placement of annular ring (SMVR), Optimal medical therapy (OMT)
- Where
- 9 sites in United States, Canada
- Volunteers
- 2 people
- Sponsor
- Duke University
Heart Failure, Congestive Heart Failure
Leveraging Home Health Aides to Improve Outcomes in Heart Failure
The purpose of the study is to determine the effectiveness of an intervention among home health aides caring for adults admitted to home care with a primary diagnosis of heart failure at VNS Health Partners in Care (home care…
- Trial name
- NCT04239911
- Testing
- mHealth app, Virtual training course
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Weill Medical College of Cornell University
Chronic Kidney Disease, End Stage Renal Disease
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
The purpose of this study is to evaluate whether cinacalcet + low dose vitamin D attenuates the progression of vascular calcification over one year, compared with a treatment regimen that includes flexible vitamin D dosing in the…
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease, Coronary Artery Calcification, Vascular Calcification
- Trial name
- NCT00379899
- Testing
- cinacalcet
- Volunteers
- 360 people
- Sponsor
- Amgen
Heart Failure With Preserved Ejection Fraction
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
- Trial name
- PARAGON-HF (NCT01920711)
- Testing
- LCZ696, Valsartan
- Where
- 715 sites in United States, Argentina and 41 more
- Volunteers
- 4,822 people
- Sponsor
- Novartis Pharmaceuticals
Atrial Fibrillation, End Stage Renal Disease
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) .
- Trial name
- RENAL-AF (NCT02942407)
- Testing
- apixaban, warfarin
- Where
- 58 sites in United States
- Volunteers
- 154 people
- Sponsor
- Christopher Granger, MD
Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload
To determine the efficacy, safety, and dose and regimen of tolvaptan in pediatric CHF patients with volume overload
- Trial name
- NCT03255226
- Testing
- Tolvaptan
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Heart Failure
C-Pulse® System European Multicenter Study
The study is designed to observe the clinical outcomes of heart failure patients treated with C-Pulse® System in the usual manner and according to the approved indications and contraindications.
- Trial name
- OPTIONS-HF (NCT01872949)
- Where
- 8 sites in Austria, Germany
- Volunteers
- 15 people
- Sponsor
- Nuwellis, Inc.
Hypertension, Heart Failure
Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules
Prazosin hydrochloride (HCl) is an oral anti-hypertensive indicated for the treatment of primary and secondary hypertension and heart failure. Pfizer Inc.
- Trial name
- NCT04967443
- Testing
- Prazosin HCl 2mg, Prazosin HCl 1 mg, Prazosin HCl 5 mg
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Pfizer
Heart Failure, Ischemic Cardiomyopathy
Scar Location and Acute Haemodynamic Response to MultiPoint Pacing Study in Patients With Ischemic Cardiomyopathy
Cardiac Resynchronization Therapy (CRT) is a proven treatment for heart failure. CRT consists of a special pacemaker with two/three leads (insulated wires which take the electrical impulses from the device to the heart), one in…
- Trial name
- NCT04066738
- Testing
- Cardiac MRI with gadolinium contrast, 3D reconstruction and location of coronary sinus venous system relative to myocardial scar, Acute haemodynamic measurements during CRT implant
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- Oxford University Hospitals NHS Trust
Coronary Artery Disease
Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure
The purpose of this study is to evaluate the effect of ivabradine on cardiovascular events in patients with coronary artery disease.
- Trial name
- SIGNIFY (NCT02446990)
- Testing
- Ivabradine
- Where
- 2 sites in Italy, United Kingdom
- Volunteers
- 19,102 people
- Sponsor
- Institut de Recherches Internationales Servier
Acute Kidney Injury
Renal Replacement Therapy and In-Hospital Mortality Incidence in Cardiac Surgery Associated Acute Kidney Injury
The goal of this study is to analyse the relation of severe acute kidney injury post cardiac surgery which characterised by the need of renal replacement therapy, with in-hospital postoperative mortality incidence.
- Trial name
- NCT06091982
- Testing
- Renal Replacement Therapy (RRT)
- Where
- Indonesia
- Volunteers
- 1,113 people
- Sponsor
- National Cardiovascular Center Harapan Kita Hospital Indonesia
Chronic Kidney Disease, CKD
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who…
- Conditions
- Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass
- Trial name
- ARTEMIS (NCT05746559)
- Testing
- Ravulizumab
- Where
- 130 sites in United States, Argentina and 18 more
- Volunteers
- 555 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.